Compare NOG & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | IRON |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | 2000 | 2020 |
| Metric | NOG | IRON |
|---|---|---|
| Price | $28.70 | $58.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $31.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 2.7M | 544.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,475,723,000.00 | N/A |
| Revenue This Year | $8.21 | N/A |
| Revenue Next Year | $4.24 | $283.52 |
| P/E Ratio | $72.97 | ★ N/A |
| Revenue Growth | ★ 11.23 | N/A |
| 52 Week Low | $19.88 | $30.82 |
| 52 Week High | $32.62 | $99.50 |
| Indicator | NOG | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 63.36 | 37.74 |
| Support Level | $26.58 | $57.81 |
| Resistance Level | $29.84 | $64.00 |
| Average True Range (ATR) | 1.14 | 2.80 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 71.78 | 12.82 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.